(unaudited)
Condensed
Statements of Three Months Ended Nine Months Ended
Operations Data September 30, September 30,
------------------------- -------------------------
2024 2023 2024 2023
----------- ----------- ----------- -----------
Revenue $ -- $ -- $ -- $ --
Operating
expenses:
Research and
development 535,162 374,200 1,214,964 1,429,757
General and
administrative 1,766,010 900,089 3,470,133 2,879,036
---------- ---------- ---------- ----------
Total
operating
expenses 2,301,172 1,274,289 4,685,097 4,308,793
---------- ---------- ---------- ----------
Loss from
operations (2,301,172) (1,274,289) (4,685,097) (4,308,793)
Other Income:
Interest income 20,488 39,215 63,245 115,951
---------- ---------- ---------- ----------
Total Other
income 20,488 39,215 63,245 115,951
---------- ---------- ---------- ----------
Net loss $(2,280,684) $(1,235,074) $(4,621,852) $(4,192,842)
========== ========== ========== ==========
Net loss per share
of common stock --
basic and diluted,
as adjusted $ (2.05) $ (1.62) $ (4.95) $ (5.63)
========== ========== ========== ==========
Weighted average
shares outstanding
-- basic and
diluted, as
adjusted 1,110,317 763,750 932,872 774,586
========== ========== ========== ==========
Condensed Balance Sheet Data September 30, December 31,
2024 2023
--------------- --------------
Cash $ 2,039,819 $ 3,316,946
Total assets 2,283,249 4,165,442
Total liabilities 1,333,818 358,548
Total stockholders' equity 949,431 3,806,894
Source: Dogwood Therapeutics, Inc.
(END) Dow Jones Newswires
November 07, 2024 07:05 ET (12:05 GMT)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。